MEA Transplant Diagnostics Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143048
- Pages: 225
-
Format:
Short Description
Middle East and Africa Transplant Diagnostics Market, By Product Type (Transplant Diagnostic Instrument, Transplant Diagnostic Software, Transplant Diagnostic Reagent), Technology (PCR-Based Molecular Assays, Sequencing-Based Molecular Assays), Transplant Type (Solid Organ Transplantation, Stem Cell Transplantation, Soft Tissue Transplantation, Bone Marrow Transplantation, Other Transplants), Application (Diagnostic Applications, Research Applications), End User (Research Laboratories and Academic Institutes, Hospital and Transplant Centers, Commercial Service Providers, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, and the Rest of the Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition
Transplant diagnostics are the immunogenetics and histocompatibility of organ and hematopoietic stem cell transplantations. These diagnostics help healthcare professionals determine compatibility between potential recipients and organ donors. These are used in various disciplines, such as immunogenetics, pathology, and infectious diseases, among others. Transplant diagnostics are used to determine whether the donor and the recipient of the organ are compatible before or after the transplant. With the introduction of transplant diagnostics, the prevalence of diseases that can cause organ failure, including both pre-and post-transplant screening, is expected to explode. The market has attracted the interest of healthcare professionals due to the many advantages these tests offer to verify suitability for a transplant procedure. Organ transplantation is one of the most popular treatment options for many end-stage renal disease patients on continuous dialysis.
In addition, it is possible to investigate organ transplantation for cases involving the heart, liver, or bone marrow. Although in many cases, there is a strong association between renal failure and liver transplantation, including end-stage renal disease. New transcriptomic, proteomic, and genomic indicators in molecular diagnostics can help to better tailor transplant therapy and early detection of rejection events. Also, strategic initiatives by market players, technological progressions in transplant diagnostics, high sterility assurance, and increasing investment in healthcare infrastructure increase the demand for transplant diagnostics.
Market Segmentation
The Middle East and Africa transplant diagnostics market is segmented into six notable segments based on product type, technology, transplant type, application, end user, and distribution channel.
On the basis of product type, the Middle East and Africa transplant diagnostics market is segmented into transplant diagnostic instrument, transplant diagnostic software, transplant diagnostic reagent
On the basis of technology, the Middle East and Africa transplant diagnostics market is segmented into PCR-based molecular assays, and sequencing-based molecular assays
On the basis of transplant type, the Middle East and Africa transplant diagnostics market is segmented into solid organ transplantation, stem cell transplantation, soft tissue transplantation, bone marrow transplantation, and other transplants
On the basis of application, the Middle East and Africa transplant diagnostics market is segmented into diagnostic applications and research applications
On the basis of end user, the Middle East and Africa transplant diagnostics market is segmented into research laboratories and academic institutes, hospitals and transplant centers, commercial service providers, and others
On the basis of distribution channel, the Middle East and Africa transplant diagnostics market is segmented into direct tender, retail sales, and others
Market Players
Some of the major players operating in the Middle East and Africa transplant diagnostics market are:
Hologic, Inc.
Biofortuna Limited
Takara Bio Inc.
Abbott
Thermo Fisher Scientific Inc.
Luminex Corporation (A subsidiary of DiaSorin Company)
DiaSorin S.p.A.
Stryker
Bio-Rad Laboratories, Inc.
Zimmer Biomet
QIAGEN
F. Hoffmann-La Roche Ltd
BIOMRIEUX
CareDx Inc.
Illumina, Inc.
IMMUCOR
TABLE OF CONTENTS
1 INTRODUCTION 74
1.1 OBJECTIVES OF THE STUDY 74
1.2 MARKET DEFINITION 74
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET 74
1.4 CURRENCY AND PRICING 77
1.5 LIMITATIONS 77
1.6 MARKETS COVERED 77
2 MARKET SEGMENTATION 83
2.1 MARKETS COVERED 83
2.2 GEOGRAPHICAL SCOPE 84
2.3 YEARS CONSIDERED FOR THE STUDY 85
2.4 DBMR TRIPOD DATA VALIDATION MODEL 86
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 89
2.6 MULTIVARIATE MODELLING 90
2.7 MARKET APPLICATION COVERAGE GRID 91
2.8 SOURCE LIFELINE CURVE 92
2.9 DBMR MARKET POSITION GRID 93
2.10 VENDOR SHARE ANALYSIS 94
2.11 SECONDARY SOURCES 95
2.12 ASSUMPTIONS 95
3 EXECUTIVE SUMMARY 96
3.1 EPIDEMOLOGY 100
3.2 PESTEL_ANALYSIS 115
3.3 PORTER'S FIVE FORCE 116
3.4 TECHNOLOGICAL INNOVATIONS 117
4 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET: REGULATIONS 118
5 KEY STRATEGIC INITIATIVES 122
6 INDUSTRIAL INSIGHTS: 123
7 MARKET OVERVIEW 125
7.1 DRIVERS 127
7.1.1 RISING NUMBER OF TRANSPLANT PROCEDURES 127
7.1.2 INCREASE IN THE TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF TRANSPLANTS 127
7.1.3 RISING HEALTHCARE SPENDING 127
7.1.4 ADOPTION OF CROSS-MATCHING AND CHIMERISM TESTING DURING PRE- AND POST-TRANSPLANTATION 128
7.2 RESTRAINTS 128
7.2.1 HIGH COST OF ORGAN TRANSPLANTATION 128
7.2.2 THE RISKS AND DIFFICULTIES OF ORGAN TRANSPLANTATION 128
7.3 OPPORTUNITIES 129
7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 129
7.3.2 RISE IN PUBLIC, PRIVATE, AND GOVERNMENT FUNDING FOR ORGAN TRANSPLANTATION 129
7.3.3 SURGE IN AWARENESS ABOUT THE IMPORTANCE OF ORGAN TRANSPLANTATION 130
7.4 CHALLENGES 131
7.4.1 ETHICAL CHALLENGES FACED DURING ORGAN TRANSPLANTATION 131
7.4.2 LACK OF ORGAN DONORS OR GAP BETWEEN ORGAN DONORS AND ORGANS NEEDED ANNUALLY 131
8 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE 133
8.1 OVERVIEW 134
8.2 TRANSPLANT DIAGNOSTIC INSTRUMENTS 137
8.2.1 AUTOMATED PIPETTORS & DISPENSERS 137
8.2.2 AUTOMATED SYSTEMS 137
8.2.2.1 NUCLEIC ACID EXTRACTION SYSTEM 138
8.2.2.2 PCR SETUP 138
8.2.2.3 OTHERS 138
8.2.3 NGS INSTRUMENTS 138
8.2.4 READERS & ANALYZERS 138
8.2.5 TRANSPLANT DIAGNOSTIC KITS 138
8.2.5.1 ASPERGILLUS SPP KITS 139
8.2.5.2 P. JIROVECII KITS 139
8.2.5.3 CMV KITS 139
8.2.5.4 EBV KITS 139
8.2.5.5 BKV KITS 140
8.2.5.6 VZV KITS 140
8.2.5.7 HSV1 KITS 140
8.2.5.8 HSV2 KITS 140
8.2.5.9 PARVOVIRUS B19 KITS 140
8.2.5.10 ADENOVIRUS KITS 140
8.2.5.11 ENTEROVIRUS KITS 140
8.2.5.12 JCV KITS 140
8.2.5.13 HHV6 KITS 140
8.2.5.14 HHV7 KITS 140
8.2.5.15 HHV8 KITS 140
8.2.5.16 TOXOPLASMA GONDII KITS 140
8.2.5.17 HEPATITIS E KITS 141
8.2.5.18 OTHER KITS 141
8.2.6 OTHER KITS 141
8.3 TRANSPLANT DIAGNOSTIC SOFTWARES 141
8.3.1 DNA SOFTWARE 142
8.3.2 NGS SOFTWARE 142
8.3.3 DATA MANAGEMENT SOFTWARE 142
8.3.4 OTHER SOFTWARES 142
8.4 TRANSPLANT DIAGNOSTIC REAGENTS 142
8.4.1 MONOCLONAL ANTIBODIES 143
8.4.2 CYTOTOXIC CONTROLS 143
8.4.3 HUMAN SERUM 143
8.4.4 OTHER REAGENTS 143
9 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY 144
9.1 OVERVIEW 145
9.2 PCR-BASED MOLECULAR ASSAYS 148
9.2.1 REAL TIME PCR 148
9.2.2 SEQUENCE-SPECIFIC PRIMER-PCR 148
9.2.3 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR 149
9.2.4 RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP) 149
9.2.5 OTHER-PCR BASED MOLECULAR ASSAYS 149
9.3 SEQUENCING-BASED MOLECULAR ASSAYS 149
9.3.1 SANGER SEQUENCING 150
9.3.2 NEXT GENERATION SEQUENCING 150
9.3.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS. 150
10 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE 151
10.1 OVERVIEW 152
10.2 SOLID ORGAN TRANSPLANTATION 155
10.2.1 KIDNEY TRANSPLANTATION 155
10.2.2 LIVER TRANSPLANTATION 155
10.2.3 HEART TRANSPLANTATION 156
10.2.4 LUNG TRANSPLANTATION 156
10.2.5 PANCREAS TRANSPLANTATION 156
10.2.6 OTHER ORGAN TRANSPLANTATIONS 156
10.3 STEM CELL TRANSPLANTATION 156
10.3.1 BONE MARROW TRANSPLANT (BMT) 157
10.3.2 PERIPHERAL BLOOD STEM CELL TRANSPLANT 157
10.3.3 CORD BLOOD TRANSPLANT 157
10.3.4 OTHER STEM CELL TRANSPLANTS 157
10.4 SOFT TISSUE TRANSPLANTATION 157
10.4.1 SKIN GRAFT 158
10.4.2 CARTILAGE TRANSPLANTATION 158
10.4.3 ADRENAL AUTOGRAFTING 158
10.4.4 OTHER SOFT TISSUE TRANSPLANTATION. 158
10.5 BONE MARROW TRANSPLANTATION 159
10.5.1 AUTOLOGOUS BONE MARROW TRANSPLANT 159
10.5.2 ALLOGENEIC BONE MARROW TRANSPLANT 159
10.5.3 UMBILICAL CORD BLOOD TRANSPLANT. 160
10.6 OTHERS 160
11 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 161
11.1 OVERVIEW 162
11.2 DIAGNOSTIC APPLICATIONS 165
11.2.1 TRANSPLANT DIAGNOSTIC INSTRUMENT 165
11.2.1.1 AUTOMATED PIPETTORS & DISPENSERS 166
11.2.1.2 AUTOMATED SYSTEMS 166
11.2.1.3 NGS INSTRUMENTS 166
11.2.1.4 READERS & ANALYZERS 166
11.2.1.5 TRANSPLANT DIAGNOSTIC KITS 166
11.2.1.6 OTHERS 166
11.2.2 TRANSPLANT DIAGNOSTIC SOFTWARE 166
11.2.2.1 DNA SOFTWARE 167
11.2.2.2 NGS SOFTWARE 167
11.2.2.3 DATA MANAGEMENT SOFTWARE 167
11.2.2.4 OTHER SOFTWARES 167
11.2.3 TRANSPLANT DIAGNOSTIC REAGENT 167
11.2.3.1 MONOCLONAL ANTIBODIES 168
11.2.3.2 CYTOTOXIC CONTROLS 168
11.2.3.3 HUMAN SERUM 168
11.2.3.4 OTHER REAGENTS 168
11.3 RESEARCH APPLICATIONS 168
11.3.1 TRANSPLANT DIAGNOSTIC INSTRUMENT 169
11.3.1.1 AUTOMATED PIPETTORS & DISPENSERS 170
11.3.1.2 AUTOMATED SYSTEMS 170
11.3.1.3 NGS INSTRUMENTS 170
11.3.1.4 READERS & ANALYZERS 170
11.3.1.5 TRANSPLANT DIAGNOSTIC KITS 170
11.3.1.6 OTHERS 170
11.3.2 TRANSPLANT DIAGNOSTIC SOFTWARE 170
11.3.2.1 DNA SOFTWARE 171
11.3.2.2 NGS SOFTWARE 171
11.3.2.3 DATA MANAGEMENT SOFTWARE 171
11.3.2.4 OTHER SOFTWARES 171
11.3.3 TRANSPLANT DIAGNOSTIC REAGENT 171
11.3.3.1 MONOCLONAL ANTIBODIES 172
11.3.3.2 CYTOTOXIC CONTROLS 172
11.3.3.3 HUMAN SERUM 172
11.3.3.4 OTHER REAGENTS 172
12 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY END USER 173
12.1 OVERVIEW 174
12.2 HOSPITALS AND TRANSPLANT CENTERS 177
12.3 COMMERCIAL SERVICE PROVIDERS 177
12.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 177
12.5 OTHERS 178
13 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 179
13.1 OVERVIEW 180
13.2 DIRECT TENDER 183
13.3 RETAIL SALES 183
13.4 OTHERS 183
14 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY REGION 185
14.1 MIDDLE EAST & AFRICA 186
14.1.1 SOUTH AFRICA 199
14.1.2 SAUDI ARABIA 211
14.1.3 U.A.E 223
14.1.4 EGYPT 235
14.1.5 ISRAEL 247
14.1.6 REST OF MIDDLE EAST AND AFRICA 259
15 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET: COMPANY LANDSCAPE 260
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 260
16 SWOT ANALYSIS 261
17 COMPANY PROFILE 262
17.1 ABBOTT 262
17.1.1 COMPANY SNAPSHOT 262
17.1.2 REVENUE ANALYSIS 262
17.1.3 COMPANY SHARE ANALYSIS 263
17.1.4 PRODUCT PORTFOLIO 263
17.1.5 RECENT DEVELOPMENTS 263
17.2 THERMO FISHER SCIENTIFIC INC. 264
17.2.1 COMPANY SNAPSHOT 264
17.2.2 REVENUE ANALYSIS 264
17.2.3 COMPANY SHARE ANALYSIS 265
17.2.4 PRODUCT PORTFOLIO 265
17.2.5 RECENT DEVELOPMENTS 267
17.3 F. HOFFMANN LA ROCHE LTD 268
17.3.1 COMPANY SNAPSHOT 268
17.3.2 REVENUE ANALYSIS 268
17.3.3 COMPANY SHARE ANALYSIS 269
17.3.4 PRODUCT PORTFOLIO 269
17.3.5 RECENT DEVELOPMENT 270
17.4 TAKARA BIO INC. 271
17.4.1 COMPANY SNAPSHOT 271
17.4.2 REVENUE ANALYSIS 271
17.4.3 COMPANY SHARE ANALYSIS 272
17.4.4 PRODUCT PORTFOLIO 272
17.4.5 RECENT DEVELOPMENTS 272
17.5 HOLOGIC, INC 273
17.5.1 COMPANY SNAPSHOT 273
17.5.2 REVENUE ANALYSIS 273
17.5.3 COMPANY SHARE ANALYSIS 274
17.5.4 PRODUCT PORTFOLIO 274
17.5.5 RECENT DEVELOPMENTS 275
17.6 ADAPTIVE BIOTECHNOLOGIES 276
17.6.1 COMPANY SNAPSHOT 276
17.6.2 REVENUE ANALYSIS 276
17.6.3 PRODUCT PORTFOLIO 277
17.6.4 RECENT DEVELOPMENT 277
17.7 ALTONA DIAGNOSTICS 278
17.7.1 COMPANY SNAPSHOT 278
17.7.2 PRODUCT PORTFOLIO 278
17.7.3 RECENT DEVELOPMENTS 278
17.8 ARQUER DIAGNOSTICS LTD 279
17.8.1 COMPANY SNAPSHOT 279
17.8.2 PRODUCT PORTFOLIO 279
17.8.3 RECENT DEVELOPMENTS 280
17.9 BAG DIAGNOSTICS GMBH 281
17.9.1 COMPANY SNAPSHOT 281
17.9.2 PRODUCT PORTFOLIO 281
17.9.3 RECENT DEVELOPMENTS 281
17.10 BIOFORTUNA LIMITED 282
17.10.1 COMPANY SNAPSHOT 282
17.10.2 PRODUCT PORTFOLIO 282
17.10.3 RECENT DEVELOPMENT 282
17.11 BIOMRIEUX 283
17.11.1 COMPANY SNAPSHOT 283
17.11.2 REVENUE ANALYSIS 283
17.11.3 PRODUCT PORTFOLIO 284
17.11.4 RECENT DEVELOPMENTS 284
17.12 BIO-RAD LABORATORIES, INC. 285
17.12.1 COMPANY SNAPSHOT 285
17.12.2 REVENUE ANALYSIS 285
17.12.3 PRODUCT PORTFOLIO 286
17.12.4 RECENT DEVELOPMENT 287
17.13 BIOTYPE GMBH 288
17.13.1 COMPANY SNAPSHOT 288
17.13.2 PRODUCT PORTFOLIO 288
17.13.3 RECENT DEVELOPMENTS 289
17.14 CAREDX INC. 290
17.14.1 COMPANY SNAPSHOT 290
17.14.2 REVENUE ANALYSIS 290
17.14.3 PRODUCT PORTFOLIO 291
17.14.4 RECENT DEVELOPMENTS 293
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
